Company Analysis Cue Biopharma, Inc.
1. Summary
Advantages
- Price (0.3248 $) is less than fair price (0.5216 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5317%).
- The stock's return over the last year (-54.79%) is lower than the sector average (-3.76%).
- Current debt level 27.57% has increased over 5 years from 7.18%.
- The company's current efficiency (ROE=-149.03%) is lower than the sector average (ROE=109.03%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Cue Biopharma, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 28.2% | -13.3% | -0.6% |
| 90 days | -58.3% | -1.6% | 2.9% |
| 1 year | -54.8% | -3.8% | 21% |
CUE vs Sector: Cue Biopharma, Inc. has significantly underperformed the "Healthcare" sector by -51.02% over the past year.
CUE vs Market: Cue Biopharma, Inc. has significantly underperformed the market by -75.77% over the past year.
Stable price: CUE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CUE with weekly volatility of -1.05% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.3248 $) is lower than the fair price (0.5216 $).
Price significantly below the fair price: The current price (0.3248 $) is 60.6% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-1.11) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (-1.11) is higher than that of the market as a whole (-68.72).
5.3. P/BV
P/BV vs Sector: The company's P/BV (3.28) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (3.28) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (6.19) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (6.19) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.17) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.17) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -1.58% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-1.58%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (-149.03%) is lower than that of the sector as a whole (109.03%).
ROE vs Market: The company's ROE (-149.03%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-86.8%) is lower than that of the sector as a whole (-2.42%).
ROA vs Market: The company's ROA (-86.8%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5317%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
